United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat

United Therapeutics’ (UTHR) fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of$6.10. Earnings rose 42% year over year on the back of higher product sales.See the Zacks Earnings Calendar to stay ahead of market-making news.United Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high-risk neuroblastoma.Revenues came in at $735.9 million, beati ...